Pulmonary function testing (PFT) is an indispensable tool in the diagnosis and management of respiratory diseases. However, interpreting these tests can be complex and challenging. This article aims to provide a comprehensive guide to understanding and interpreting PFT results.
PFT includes various tests such as spirometry, lung volumes, and diffusion capacity. Spirometry measures the amount (volume) and speed (flow) of air that can be inhaled and exhaled. Lung volumes provide information about the size of the lungs, and diffusion capacity assesses how well gases are being exchanged between the lungs and the bloodstream.
Spirometry results are expressed in terms of FEV1 (Forced Expiratory Volume in the first second) and FVC (Forced Vital Capacity). The ratio of FEV1/FVC is used to identify obstructive disorders. A ratio of less than 70% indicates obstruction. The severity of obstruction is further classified based on the percentage of predicted FEV1.
Lung volumes can be measured directly or indirectly. An increase in residual volume (RV) or total lung capacity (TLC) suggests air trapping or hyperinflation, commonly seen in obstructive disorders. A decrease in TLC may indicate restrictive lung disease.
Diffusion capacity of the lung for carbon monoxide (DLCO) is a sensitive measure of the lung's gas exchange capacity. A reduced DLCO could signify interstitial lung disease, pulmonary vascular disease, or emphysema.
Interpreting PFTs requires an understanding of the various components and their implications in different disease states. By applying this knowledge, healthcare professionals can make accurate diagnoses, monitor disease progression, and guide treatment strategies. Continued education and practice in PFT interpretation will enhance clinical competence and improve patient care.
1.
Parkinson patient's gait is restored by a spinal cord stimulator.
2.
Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?
3.
automated, precise reporting for clonality testing using NGS.
4.
Are Microplastics Feeding Cancer Risk?
5.
Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.
1.
Understanding Protein C Deficiency: Symptoms, Causes, and Treatment
2.
Tumor Dormancy and Cancer Recurrence: Mechanisms, Clinical Implications, and Future Directions
3.
Immune Microenvironment Biomarkers for Early Tumor Evolution
4.
The Future of Oncology: Innovations Every Doctor Should Know
5.
What You Need to Know About the Early Warning Signs of Colon Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
5.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation